Cargando…

Informing Pharmacokinetic Models With Physiological Data: Oral Population Modeling of L-Serine in Humans

To determine how to set optimal oral L-serine (serine) dose levels for a clinical trial, existing literature was surveyed. Data sufficient to set the dose was inadequate, and so an (n = 10) phase I-A calibration trial was performed, administering serine with and without other oral agents. We analyze...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosley, J. R., Björnson, Elias, Zhang, Cheng, Turkez, Hasan, Nielsen, Jens, Uhlen, Mathias, Borén, Jan, Mardinoglu, Adil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156419/
https://www.ncbi.nlm.nih.gov/pubmed/34054524
http://dx.doi.org/10.3389/fphar.2021.643179
_version_ 1783699440971808768
author Bosley, J. R.
Björnson, Elias
Zhang, Cheng
Turkez, Hasan
Nielsen, Jens
Uhlen, Mathias
Borén, Jan
Mardinoglu, Adil
author_facet Bosley, J. R.
Björnson, Elias
Zhang, Cheng
Turkez, Hasan
Nielsen, Jens
Uhlen, Mathias
Borén, Jan
Mardinoglu, Adil
author_sort Bosley, J. R.
collection PubMed
description To determine how to set optimal oral L-serine (serine) dose levels for a clinical trial, existing literature was surveyed. Data sufficient to set the dose was inadequate, and so an (n = 10) phase I-A calibration trial was performed, administering serine with and without other oral agents. We analyzed the trial and the literature data using pharmacokinetic (PK) modeling and statistical analysis. The therapeutic goal is to modulate specific serine-related metabolic pathways in the liver using the lowest possible dose which gives the desired effect since the upper bound was expected to be limited by toxicity. A standard PK approach, in which a common model structure was selected using a fit to data, yielded a model with a single central compartment corresponding to plasma, clearance from that compartment, and an endogenous source of serine. To improve conditioning, a parametric structure was changed to estimate ratios (bioavailability over volume, for example). Model fit quality was improved and the uncertainty in estimated parameters was reduced. Because of the particular interest in the fate of serine, the model was used to estimate whether serine is consumed in the gut, absorbed by the liver, or entered the blood in either a free state, or in a protein- or tissue-bound state that is not measured by our assay. The PK model structure was set up to represent relevant physiology, and this quantitative systems biology approach allowed a broader set of physiological data to be used to narrow parameter and prediction confidence intervals, and to better understand the biological meaning of the data. The model results allowed us to determine the optimal human dose for future trials, including a trial design component including IV and tracer studies. A key contribution is that we were able to use human physiological data from the literature to inform the PK model and to set reasonable bounds on parameters, and to improve model conditioning. Leveraging literature data produced a more predictive, useful model.
format Online
Article
Text
id pubmed-8156419
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81564192021-05-28 Informing Pharmacokinetic Models With Physiological Data: Oral Population Modeling of L-Serine in Humans Bosley, J. R. Björnson, Elias Zhang, Cheng Turkez, Hasan Nielsen, Jens Uhlen, Mathias Borén, Jan Mardinoglu, Adil Front Pharmacol Pharmacology To determine how to set optimal oral L-serine (serine) dose levels for a clinical trial, existing literature was surveyed. Data sufficient to set the dose was inadequate, and so an (n = 10) phase I-A calibration trial was performed, administering serine with and without other oral agents. We analyzed the trial and the literature data using pharmacokinetic (PK) modeling and statistical analysis. The therapeutic goal is to modulate specific serine-related metabolic pathways in the liver using the lowest possible dose which gives the desired effect since the upper bound was expected to be limited by toxicity. A standard PK approach, in which a common model structure was selected using a fit to data, yielded a model with a single central compartment corresponding to plasma, clearance from that compartment, and an endogenous source of serine. To improve conditioning, a parametric structure was changed to estimate ratios (bioavailability over volume, for example). Model fit quality was improved and the uncertainty in estimated parameters was reduced. Because of the particular interest in the fate of serine, the model was used to estimate whether serine is consumed in the gut, absorbed by the liver, or entered the blood in either a free state, or in a protein- or tissue-bound state that is not measured by our assay. The PK model structure was set up to represent relevant physiology, and this quantitative systems biology approach allowed a broader set of physiological data to be used to narrow parameter and prediction confidence intervals, and to better understand the biological meaning of the data. The model results allowed us to determine the optimal human dose for future trials, including a trial design component including IV and tracer studies. A key contribution is that we were able to use human physiological data from the literature to inform the PK model and to set reasonable bounds on parameters, and to improve model conditioning. Leveraging literature data produced a more predictive, useful model. Frontiers Media S.A. 2021-05-13 /pmc/articles/PMC8156419/ /pubmed/34054524 http://dx.doi.org/10.3389/fphar.2021.643179 Text en Copyright © 2021 Bosley, Björnson, Zhang, Turkez, Nielsen, Uhlen, Borén and Mardinoglu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Bosley, J. R.
Björnson, Elias
Zhang, Cheng
Turkez, Hasan
Nielsen, Jens
Uhlen, Mathias
Borén, Jan
Mardinoglu, Adil
Informing Pharmacokinetic Models With Physiological Data: Oral Population Modeling of L-Serine in Humans
title Informing Pharmacokinetic Models With Physiological Data: Oral Population Modeling of L-Serine in Humans
title_full Informing Pharmacokinetic Models With Physiological Data: Oral Population Modeling of L-Serine in Humans
title_fullStr Informing Pharmacokinetic Models With Physiological Data: Oral Population Modeling of L-Serine in Humans
title_full_unstemmed Informing Pharmacokinetic Models With Physiological Data: Oral Population Modeling of L-Serine in Humans
title_short Informing Pharmacokinetic Models With Physiological Data: Oral Population Modeling of L-Serine in Humans
title_sort informing pharmacokinetic models with physiological data: oral population modeling of l-serine in humans
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156419/
https://www.ncbi.nlm.nih.gov/pubmed/34054524
http://dx.doi.org/10.3389/fphar.2021.643179
work_keys_str_mv AT bosleyjr informingpharmacokineticmodelswithphysiologicaldataoralpopulationmodelingoflserineinhumans
AT bjornsonelias informingpharmacokineticmodelswithphysiologicaldataoralpopulationmodelingoflserineinhumans
AT zhangcheng informingpharmacokineticmodelswithphysiologicaldataoralpopulationmodelingoflserineinhumans
AT turkezhasan informingpharmacokineticmodelswithphysiologicaldataoralpopulationmodelingoflserineinhumans
AT nielsenjens informingpharmacokineticmodelswithphysiologicaldataoralpopulationmodelingoflserineinhumans
AT uhlenmathias informingpharmacokineticmodelswithphysiologicaldataoralpopulationmodelingoflserineinhumans
AT borenjan informingpharmacokineticmodelswithphysiologicaldataoralpopulationmodelingoflserineinhumans
AT mardinogluadil informingpharmacokineticmodelswithphysiologicaldataoralpopulationmodelingoflserineinhumans